W E L C O M E T O
C A P T I G E N I C S C A P I T A L INVESTING IN THE FUTURE
A F I N A N C I A L I N V E S T M E N T
C O M P A N Y I N S T O C K H O L M S W E D E NCAPTIGENICS CAPITAL
Welcome to our financial investment company. Here, we aim to provide you with valuable information about our investments. Our team is composed of experienced and dedicated professionals, who have achieved great success in the medical innovation industry.
FINANCIAL INVESTMENTS
Captigenics Capital owns the majority of
AUXESIS PHARMA HOLDING (publ),
a pharmaceutical company based in Stockholm, Sweden.
LIFE SCIENCE TREND REPORT
The life sciences industry comprises companies operating in the research, development and manufacturing of pharmaceuticals, biotechnology, medicines, medical devices, biomedical technologies, nutraceuticals, cosmeceuticals, food processing, and other products that improve the lives of organisms.
RESEARCH & INNOVATION
AUXESIS PHARMA HOLDING AB (publ) is a public company focusing on medical research and Life Science on humans and animals. Life Science is an expanding industry with a non-cyclical market. The growth potential is presently higher than in most other sectors.
PARTNERSHIP
In October 2023 the company will submit an application for a patent to the Patent and Registration Office Sweden. When it is ready, the plans are directed towards Östersund.
OUR COMPANIES
AUXESIS PHARMA AB (publ)
Auxesis Pharma Holding AB was founded in 2019 as a Life Science innovation company interdisciplinary in the medical industry and is now the parent company of CoxyPet Pharma AB.
COXYPET PHARMA AB
CoxyPet Pharma AB was established in 2018 to be able to enter the animal care sector. The aim for CoxyPet Pharma AB company is to develop pain elimination products for the veterinary and animal care markets.
